EUSense
Transforming GI Cancer diagnosis and treatment with AI for endoscopic ultrasound
Company Overview
Snapshot
Founded in July 2024 by Tamar Rucham, EUSense operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing AI for endoscopic ultrasound in GI cancer diagnosis and treatment. EUSense ceased operations in December 2025.
Business overview
EUSense is a Health Tech & Life Sciences company developing AI solutions for gastrointestinal cancer diagnosis and treatment. The company's core technology leverages artificial intelligence, including deep learning, computer vision, and image recognition, to enhance endoscopic ultrasound (EUS) procedures. This technology aims to improve the detection of pancreatic abnormalities and malignancy classification, making advanced treatments more accessible and effective for patients worldwide. EUSense primarily serves the healthcare and life sciences industries, operating within the digital healthcare sector.
Company Intelligence Q&A
- What is EUSense's primary focus?
- EUSense focuses on transforming GI cancer diagnosis and treatment through the application of AI for endoscopic ultrasound, aiming to make advanced cancer treatments more accessible.
- When was EUSense founded?
- EUSense was founded in July 2024.
- Who is the founder of EUSense?
- Tamar Rucham is the founder of EUSense.
- What is the status of EUSense?
- EUSense is currently non-active and ceased to operate in December 2025.
- What technology does EUSense utilize?
- EUSense utilizes patent-pending AI, developed at Clalit, which excels at detecting pancreatic abnormalities and shows promising results in malignancy classification.